

Table 23.8
Cancer of the Prostate (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

| | All Races, Males | | | White Males | | | Black Males | | |
|--|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| | All | <65 | 65+ | All | <65 | 65+ | All | <65 | 65+ |
| 5-Year Relative Survival (Percent) | | | | | | | | | |
| Year of Diagnosis: | | | | | | | | | |
| 1960-1963 ^a | - | - | - | 50 | - | - | 35 | - | - |
| 1970-1973 ^a | - | - | - | 63 | - | - | 55 | - | - |
| 1975-1977 ^b | 67.8 | 73.4 | 66.1 | 68.5 | 75.2 | 66.6 | 60.7 | 62.0 | 60.1 |
| 1978-1980 ^b | 70.1 | 75.2 | 68.6 | 71.2 | 76.7 | 69.6 | 62.1 | 65.0 | 60.6 |
| 1981-1983 ^b | 72.0 | 76.0 | 70.9 | 73.1 | 77.6 | 71.9 | 62.8 | 65.0 | 61.9 |
| 1984-1986 ^b | 75.1 | 77.2 | 74.5 | 76.3 | 78.9 | 75.6 | 65.6 | 67.2 | 64.9 |
| 1987-1989 ^b | 82.8 | 83.2 | 82.7 | 84.4 | 84.7 | 84.3 | 71.2 | 72.8 | 70.7 |
| 1990-1992 ^b | 92.9 | 92.9 | 92.9 | 94.1 | 94.0 | 94.1 | 84.5 | 86.8 | 83.6 |
| 1993-1995 ^b | 95.2 | 95.9 | 94.9 | 96.0 | 96.5 | 95.7 | 91.9 | 93.4 | 91.0 |
| 1996-1998 ^b | 97.3 | 98.5 | 96.7 | 97.9 | 98.9 | 97.3 | 95.0 | 96.7 | 93.7 |
| 1999-2001 ^b | 99.3 | 99.1 | 99.3 | 99.7 | 99.5 | 99.6 | 97.4 | 98.1 | 96.4 |
| 2002-2004 ^b | 99.6 | 99.5 | 99.7 | 99.8 | 99.6 | 99.7 | 98.0 | 99.2 | 96.3 |
| 2005-2009 ^b | 99.5 | 99.6 | 99.4 | 99.8 | 99.9 | 99.6 | 98.3 | 98.6 | 97.8 |
| 2010-2016 ^b | 98.3 ^f | 99.0 ^f | 97.7 ^f | 98.7 ^f | 99.4 ^f | 98.1 ^f | 96.3 ^f | 97.5 ^f | 94.4 ^f |
| 5-Year Period Survival (Percent) ^{cd} | | | | | | | | | |
| 2016 | 97.3 | 97.9 | 96.8 | 97.2 | 98.0 | 96.6 | 95.9 | 97.2 | 94.2 |
| Stage Distribution (%) 2010-2016 ^{ce} | | | | | | | | | |
| All Stages | | | | | | | | | |
| Number of cases | 332,075 | 145,886 | 186,189 | 248,870 | 104,945 | 143,925 | 53,305 | 29,514 | 23,791 |
| Percent | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Localized | 76 | 77 | 75 | 76 | 77 | 76 | 78 | 79 | 78 |
| Regional | 13 | 16 | 11 | 14 | 17 | 12 | 11 | 14 | 8 |
| Distant | 6 | 4 | 8 | 6 | 4 | 8 | 7 | 5 | 9 |
| Unstaged/Unknown | 5 | 3 | 6 | 4 | 2 | 5 | 4 | 3 | 5 |
| 5-Year Relative Survival (Percent), 2010-2016 ^c | | | | | | | | | |
| Age at Diagnosis: | | | | | | | | | |
| Ages <45 | 96.1 | - | - | 95.0 | - | - | 97.7 | - | - |
| Ages 45-54 | 97.3 | - | - | 96.9 | - | - | 97.9 | - | - |
| Ages 55-64 | 98.5 | - | - | 98.7 | - | - | 97.2 | - | - |
| Ages 65-74 | 100.0 | - | - | 100.0 | - | - | 97.6 | - | - |
| Ages 75+ | 90.9 | - | - | 90.4 | - | - | 84.7 | - | - |
| Ages <65 | 98.2 | - | - | 98.3 | - | - | 97.5 | - | - |
| Ages 65+ | 97.5 | - | - | 97.4 | - | - | 94.5 | - | - |
| Stage ^e : | | | | | | | | | |
| All Stages | 97.8 | 98.2 | 97.5 | 97.8 | 98.3 | 97.4 | 96.2 | 97.5 | 94.5 |
| Localized | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Regional | 100.0 | 99.7 | 100.0 | 100.0 | 99.6 | 100.0 | 100.0 | 100.0 | 99.7 |
| Distant | 30.2 | 33.5 | 28.8 | 29.5 | 32.7 | 28.3 | 29.9 | 33.6 | 27.0 |
| Unstaged/Unknown | 83.3 | 92.4 | 79.8 | 76.8 | 89.7 | 72.5 | 74.4 | 86.9 | 66.7 |

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.⁻ Statistic could not be calculated due to fewer than 25 cases during the time period.